Quick Answer
MoonLake Immunotherapeutics reported Net Income Loss of -$227.32 million for the year ending 2025.
- MoonLake Immunotherapeutics showed a decrease of -91.1% in Net Income Loss from 2024 to 2025.
- This data is from MoonLake Immunotherapeutics's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), MoonLake Immunotherapeutics's Net Income Loss has declined by 4,904.1%.
- Historical annual values: Fiscal year 2025: -$227.32 million | Fiscal year 2024: -$118.94 million | Fiscal year 2023: -$36.01 million | Fiscal year 2022: -$49.97 million | Fiscal year 2021: -$4.54 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: